# MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis

> **NCT06434376** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Second Affiliated Hospital of Wenzhou Medical University** · enrollment: 10 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Conventional chemotherapy combined with personalized immune regulation diagnosis and treatment technology

## Key facts

- **NCT ID:** NCT06434376
- **Lead sponsor:** Second Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-07-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06434376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06434376, "MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06434376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*